A second recent study confirmed and extended these findings [180], showing that about 80% of SCCOHT tumor samples exhibit strong EZH2 expression by immunohistochemistry; re-expression of SMARCA4 in these cells reduced EZH2 expression [180]. This evidence concerns the gene EZH2 and neoplasm.